NCT03985345

Brief Summary

After birth, the perineum has to be trained in order to recover its functions. This study is designed to assess the quality of life evolution with the EMY connected device. The secondary purposes are to evaluate patient compliance to the EMY probe, to observe the evolution of urine scores over the duration of the trial in order to consider a comparative study thereafter, and to evaluate the interest of using the EMY connected perineal probe in the context of stress urinary incontinence.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 5, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 13, 2019

Completed
3 months until next milestone

Study Start

First participant enrolled

September 2, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 9, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 9, 2020

Completed
Last Updated

October 1, 2025

Status Verified

September 1, 2025

Enrollment Period

1 year

First QC Date

June 5, 2019

Last Update Submit

September 26, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Contilife questionnaire

    A quality of life questionnaire will be used to follow the quality of life evolution for patients with stress urinary incontinence (UI) using the EMY device.

    The change of the quality of life will be assessed : completion of Contilife questionnaire at the inclusion visit (Day 0), one month after inclusion visit (Month1), 2 months after inclusion visit (Month2) and 3 months after inclusion (Month3).

Secondary Outcomes (4)

  • The patient compliance to the EMY device

    Patients will complete the tracking notebook each time they use the EMY device during 3 months of the clinical research study (from inclusion, until visit Month3).

  • The urinary scores

    The change in the urinary scores will be assessed. The ICIQ-SF questionnaire will be completed by patients at the inclusion visit (Day0) and on visits Month1, Month2 and Month3.

  • The interest of using the EMY connected perineal device in the context of stress urinary incontinence

    The PGI-I questionnaire will be completed at visit Month3 (3 monhs after inclusion visit).

  • The interest of using the EMY connected perineal device in the context of stress urinary incontinence

    The questionnaire of interest will be completed at visit Month3 (3 monhs after inclusion visit).

Study Arms (1)

EMY Probe

EXPERIMENTAL
Device: intravaginal device (probe) EMY

Interventions

Free use of EMY and its mobile application for 10 minutes during 5 different days per week.

EMY Probe

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women with urinary leakage, at least once a week or more since more than 3 months
  • Women aged 18 and over, no upper age limit
  • Patient having given birth since 6 months minimum
  • Patient able to do an effective voluntary contraction and avoiding abdominal synergy and apnea during contraction (attested by the health professional partner who leads the patient to the study)
  • Patient who has responded favorably to a perineal reeducation with at least 2 sessions (attested by the health professional partner who leads the patient to the clinical study), rehabilitation of stress urinary incontinence or mixed incontinence with predominance of stress urinary incontinence
  • Signed informed consent form
  • Effective contraception throughout the study (declarative)
  • The patient must have a smartphone running at least the Android 5 and iOS 8 versions
  • The patient must know how to read and write French

You may not qualify if:

  • Patient practicing any other perineal reeducation during the study period
  • Patient with neurological disease or congenital malformation, urinary incontinence or prolapse treated surgically or medically or perineal hypoesthesia or local conditions that prohibit the use of an intravaginal device
  • Patient with an urge urinary incontinence or mixed urinary incontinence with a predominance of urgency.
  • Contraindication to the use of the medical device
  • Patient with Genito-urinary cancer (in the last 5 years)
  • Patient with extra-uretral "incontinence" (fistula, ectopic ureter)
  • Patient with severe urinary retention
  • Patient carrying a sacral neuromodulation case
  • Impossibility to give the patient clear information (patient in emergency situation, patient with difficulties for understanding, ...)
  • Patient under the protection of justice
  • Patient under guardianship or curatorship
  • Pregnancy (positive urine test)
  • Breastfeeding patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Strasbourg University Hospitals

Strasbourg, 67091, France

Location

Related Publications (1)

  • Jochum F, Garbin O, Godet J, Ragueneau M, Meyer C, Billecocq S, Lecointre L, Akladios C, Host A. Prospective evaluation of the connected biofeedback EMY Kegel trainer in the management of stress urinary incontinence. J Gynecol Obstet Hum Reprod. 2022 Feb;51(2):102280. doi: 10.1016/j.jogoh.2021.102280. Epub 2021 Dec 1.

    PMID: 34861424BACKGROUND

MeSH Terms

Conditions

Urinary Incontinence, Stress

Condition Hierarchy (Ancestors)

Urinary IncontinenceUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 5, 2019

First Posted

June 13, 2019

Study Start

September 2, 2019

Primary Completion

September 9, 2020

Study Completion

September 9, 2020

Last Updated

October 1, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations